BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week Low – Here’s Why

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $7.60 and last traded at $7.74, with a volume of 48091 shares changing hands. The stock had previously closed at $8.13.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BBOT. Canaccord Genuity Group began coverage on BridgeBio Oncology Therapeutics in a research report on Monday. They set a “buy” rating and a $23.00 target price on the stock. Weiss Ratings started coverage on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They set a “sell (d+)” rating for the company. HC Wainwright increased their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Finally, Stifel Nicolaus started coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 price target for the company. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

BridgeBio Oncology Therapeutics Price Performance

The company has a 50-day simple moving average of $9.01. The firm has a market capitalization of $644.48 million, a price-to-earnings ratio of -5.27 and a beta of 0.22.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. As a group, analysts expect that BridgeBio Oncology Therapeutics, Inc will post -2.19 earnings per share for the current year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

A number of large investors have recently modified their holdings of the business. CIBC Private Wealth Group LLC purchased a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth about $63,000. XTX Topco Ltd lifted its stake in shares of BridgeBio Oncology Therapeutics by 22.4% during the fourth quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock worth $358,000 after buying an additional 5,249 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth $107,000. Squarepoint Ops LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth $144,000. Finally, Quadrature Capital Ltd acquired a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at $162,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.